Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Gene-Targeting drug hopes to tame rare childhood epilepsy

NCT ID NCT07363603

First seen Jan 23, 2026 · Last updated May 24, 2026 · Updated 21 times

Summary

This early-stage trial tests an experimental drug called ASO-GNAO1 (Tianasen) in 5 children aged 1-14 with a specific GNAO1 gene mutation that causes severe epilepsy and uncontrolled movements. The drug is given via spinal injections over 12 months to see if it can reduce seizures and movement episodes. Because the disease is very rare and serious, all participants receive the active drug, and the study focuses on safety and finding the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University

    RECRUITING

    Moscow, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.